Q32 Bio (Q32 Bio) Additional Paid-In Capital : $234.82 Mil(As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Additional Paid-In Capital?

Q32 Bio's quarterly additional paid-in capital increased from Sep. 2023 ($3.56 Mil) to Dec. 2023 ($4.16 Mil) and increased from Dec. 2023 ($4.16 Mil) to Mar. 2024 ($234.82 Mil).

Q32 Bio's annual additional paid-in capital increased from Dec. 2021 ($1.32 Mil) to Dec. 2022 ($2.63 Mil) and increased from Dec. 2022 ($2.63 Mil) to Dec. 2023 ($4.16 Mil).

Q32 Bio Additional Paid-In Capital Historical Data

The historical data trend for Q32 Bio's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Additional Paid-In Capital Chart

Q32 Bio Annual Data

Trend

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.32

2.63

4.16

Q32 Bio Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial			2.63	-	3.56	4.16	234.82

Q32 Bio Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Q32 Bio Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.q32bio.com

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024